Omexac-20/Omexac-40 Drug Interactions



D & G Pharma


D & G Pharma
Full Prescribing Info
Drug Interactions
Omexac-40: Nelfinavir, atazanavir: The plasma levels of nelfinavir and atazanavir are decreased in case of co-administration with Omeprazole.
Digoxin: Concomitant treatment with Omeprazole (20 mg daily) and digoxin in healthy subjects increased the bioavailability of digoxin by 10%. Digoxin toxicity has been rarely reported.
Clopidogrel: Results from studies in healthy subjects have shown a pharmacokinetic (PK)/pharmacodynamic (PD) interaction between clopidogrel (300 mg loading dose/75 mg daily maintenance dose) and Omeprazole (80 mg p.o. daily) resulting in a decreased exposure to the active metabolite of clopidogrel by an average of 46% and a decreased maximum inhibition of (ADP induced) platelet aggregation by an average of 16%.
Other active substances: The absorption of Posaconazole, Erlotinib, Ketoconazole and Itraconazole is significantly reduced and thus clinical efficacy may be impaired. For Posaconazole and Erlotinib concomitant use should be avoided.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in